04.19.26 -- Yesterday's Product Launch Strategies Won't Work Tomorrow

Happy Sunday! My weekend selections from Life Science Leader run the gamut from government funding of early-stage biotech to FDA policymaking and launching a new drug successfully. On commercial launches, too many new products disappoint, a fate that’s avoidable by understanding shifts in the commercial market and doing things differently.

Speaking of doing things differently, my colleague Louis Garguilo wrote a provocative article that looks at what could happen if the U.S. government stopped funding biotech. In a follow-up article, Garguilo suggests that perhaps the biotech business model should adapt to “blossom on sturdier vines, those that don’t rely on government watering.”

Changing government policy was the subject of a recent episode of the Business of Biotech, specifically how FDA regulations governing biosimilars have changed over the last 15 years. Dr. Sarfaraz Niazi, Ph.D. was a catalyst in some of those changes, and potentially more to come.

Check out a curated selection from our partners, below, and thanks for reading.

Ben Comer     
Chief Editor, Life Science Leader

Cencora explains how evolving EU ATMP rules force U.S. CGT developers to rethink timelines, funding assumptions, and approval strategies. (More)

BioPhorum shows how disciplined AI governance protects innovation funding while meeting rising regulatory expectations across GxP environments. (More)

North Carolina Biotechnology Center stresses sustained investment, aligned policy, and coordinated ecosystems to keep global competitiveness. (More)

Ergomed Clinical Research connects inclusion mandates to stronger data, faster enrollment, and regulatory confidence that protects development investment. (More)

EmVenio Clinical Research outlines how FDA diversity guidance reshapes trial design, budgets, and evidence standards. (More)

Citeline highlights how plain‑language disclosure is becoming a regulatory expectation that influences trust, timelines, and global trial strategy. (More)

Mural Health reflects on which operational and regulatory shifts proved real as funding pressure reshaped participant‑centric trial models. (More)